ALLR Key Statistics, Chart & Performance
The current stock price of ALLR is 1.14 USD. In the past month the price decreased by -0.87%. In the past year, price increased by 8.57%.
ALLR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.25 | 388.38B | ||
| AMGN | AMGEN INC | 14.73 | 173.51B | ||
| GILD | GILEAD SCIENCES INC | 14.88 | 151.23B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.19 | 115.35B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.86 | 79.74B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 731.13 | 49.26B | ||
| INSM | INSMED INC | N/A | 35.17B | ||
| NTRA | NATERA INC | N/A | 32.75B | ||
| BIIB | BIOGEN INC | 10.71 | 26.30B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.97B | ||
| INCY | INCYTE CORP | 16.36 | 20.62B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18 | 20.46B |
Related stock screener links
About ALLR
Company Profile
Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company is headquartered in Boston, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2021-12-21. The company is focused on development of stenoparib, a PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP technology to develop a companion diagnostic that can be used to select those patients expected to derive clinical benefit from stenoparib. Its therapeutic candidate, stenoparib, is a dual inhibitor of the key DNA damage repair enzyme PARP, as well as Tankyrases, critical enzymes involved in the WNT signaling pathway commonly activated in many cancers. Inhibition of key DNA damage repair enzymes, such as PARP, has clinically demonstrated to be therapeutically beneficial in the treatment of cancers (ovarian cancers). The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes.
Company Info
ALLARITY THERAPEUTICS INC
24 School St., 2Nd Floor
Boston MASSACHUSETTS US
Employees: 6
Phone: 14014264664
ALLARITY THERAPEUTICS INC / ALLR FAQ
Can you describe the business of ALLARITY THERAPEUTICS INC?
Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company is headquartered in Boston, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2021-12-21. The company is focused on development of stenoparib, a PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP technology to develop a companion diagnostic that can be used to select those patients expected to derive clinical benefit from stenoparib. Its therapeutic candidate, stenoparib, is a dual inhibitor of the key DNA damage repair enzyme PARP, as well as Tankyrases, critical enzymes involved in the WNT signaling pathway commonly activated in many cancers. Inhibition of key DNA damage repair enzymes, such as PARP, has clinically demonstrated to be therapeutically beneficial in the treatment of cancers (ovarian cancers). The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes.
Can you provide the latest stock price for ALLARITY THERAPEUTICS INC?
The current stock price of ALLR is 1.14 USD.
Does ALLR stock pay dividends?
ALLR does not pay a dividend.
What is the ChartMill technical and fundamental rating of ALLR stock?
ALLR has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
How many employees does ALLARITY THERAPEUTICS INC have?
ALLARITY THERAPEUTICS INC (ALLR) currently has 6 employees.
What is ALLARITY THERAPEUTICS INC worth?
ALLARITY THERAPEUTICS INC (ALLR) has a market capitalization of 18.02M USD. This makes ALLR a Nano Cap stock.
ALLR Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ALLR. When comparing the yearly performance of all stocks, ALLR is a bad performer in the overall market: 76.1% of all stocks are doing better.
ALLR Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ALLR Forecast & Estimates
7 analysts have analysed ALLR and the average price target is 9.69 USD. This implies a price increase of 750% is expected in the next year compared to the current price of 1.14.